STOCK AND WARRANT PURCHASE AGREEMENTStock and Warrant Purchase Agreement • January 12th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • New York
Contract Type FiledJanuary 12th, 2016 Company Industry JurisdictionThis Stock and Warrant Purchase Agreement (“Agreement”) is made and entered into this 7th day of January, 2016, by and between PharmaCyte Biotech, Inc., a Nevada corporation, with a business address of 12510 Prosperity Drive, Suite 310, Silver Spring, Maryland 20904 (“Seller”), and Berkshire Capital Management Co., Inc., a Delaware corporation, with a business address of 670 White Plains Road, Suite 120, Scarsdale New York 10583 (“Purchaser”). Both Seller and Purchaser are referred to individually as a “Party” and jointly as the “Parties.”
PHARMACYTE BIOTECH, INC. COMMON STOCK WARRANT AGREEMENTCommon Stock Warrant Agreement • January 12th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
Contract Type FiledJanuary 12th, 2016 Company IndustryThis Common Stock Warrant Agreement (“Warrant Agreement”) certifies that, for value received, Berkshire Capital Management Co., Inc., a Delaware corporation, or its assigns (“Holder”) is entitled to purchase from PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), up to a total of 8,500,000 shares of Common Stock (as defined below) (each, a “Warrant” and collectively, the “Warrants,” and each such share of Common Stock, a “Warrant Security” and all such shares of Common Stock, the “Warrant Securities”), at any time and from time to time through and including January 7, 2021 (“Expiration Date”), all on the terms and subject to the conditions set forth below: